Integrating semaglutide into obesity management – a primary care perspective

References

• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief: no. 3602020.
   Google Scholar
• Upadhyay J, Farr O, Perakakis N, et al. Obesity as a disease. Med Clin North Am. 2018;102(1):13–33.
   PubMed Web of Science ®Google Scholar
• Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40–66.
   PubMed Web of Science ®Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
   PubMed Web of Science ®Google Scholar
• Semlitsch T, Stigler FL, Jeitler K, et al. Management of overweight and obesity in primary care-a systematic overview of international evidence-based guidelines. Obes Rev. 2019;20(9):1218–1230.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Hobbs TM, Chagin KM, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017;7(11):e017583.
   PubMed Web of Science ®Google Scholar
• Kahan SI. Practical strategies for engaging individuals with obesity in primary care. Mayo Clin Proc. 2018;93(3):351–359.
   PubMed Web of Science ®Google Scholar
• Mastrocola MR, Roque SS, Benning LV, et al. Obesity education in medical schools, residencies, and fellowships throughout the world: a systematic review. Int J Obes (Lond). 2020;44(2):269–279.
   PubMed Web of Science ®Google Scholar
• Orjuela-Grimm M, Butsch WS, Bhatt-Carreño S, et al. Benchmarking of provider competencies and current training for prevention and management of obesity among family medicine residency programs: a cross-sectional survey. BMC Fam Pract. 2021;22(1):132.
   PubMed Web of Science ®Google Scholar
• Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6(3):237–248.
   PubMed Web of Science ®Google Scholar
• Forgione N, Deed G, Kilov G, et al. Managing obesity in primary care: breaking down the barriers. Adv Ther. 2018;35(2):191–198.
   PubMed Web of Science ®Google Scholar
• Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875–E891.
   PubMed Web of Science ®Google Scholar
• Casanova D, Kushner RF, Ciemins EL, et al. Building successful models in primary care to improve the management of adult patients with obesity. Popul Health Manag. 2021;24(5):548–559.
   PubMed Web of Science ®Google Scholar
• Gallagher C, Corl A, Dietz WH. Weight can’t wait: a guide to discussing obesity and organizing treatment in the primary care setting. Obesity (Silver Spring). 2021;29(5):821–824.
   PubMed Web of Science ®Google Scholar
• Tucker S, Bramante C, Conroy M, et al. The most undertreated chronic disease: addressing obesity in primary care settings. Curr Obes Rep. 2021;10(3):396–408.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick SL, Wischenka D, Appelhans BM, et al. An evidence-based guide for obesity treatment in primary care. Am J Med. 2016;129(1):115.e1–7.
   PubMed Web of Science ®Google Scholar
• Bays HE, McCarthy W, Burridge K, et al. Obesity algorithm eBook, presented by the Obesity Medicine Association. 2021 [cited 2021 Dec 1]. Available from: https://obesitymedicine.org/obesity-algorithm/
   Google Scholar
• Vallis M, Piccinini-Vallis H, Sharma AM, et al. Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Can Fam Physician. 2013;59(1):27–31.
   PubMed Web of Science ®Google Scholar
• Reims K, Ernst D. Using motivational interviewing to promote healthy weight. Fam Pract Manag. 2016;23(5):32–38.
   PubMedGoogle Scholar
• Heckman CJ. Motivational interviewing in health care: helping patients change behavior. Written by S Rollnick, WR Miller, CC Butler. Guilford Press, New York, 2008. Psycho-Oncology. 2009;18(1):110–111.
   Web of Science ®Google Scholar
• Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485–497.
   PubMed Web of Science ®Google Scholar
• Sabin JA, Marini M, Nosek BA. Implicit and explicit anti-fat bias among a large sample of medical doctors by BMI, race/ethnicity and gender. PLoS One. 2012;7(11):e48448.
   PubMed Web of Science ®Google Scholar
• Lawrence BJ, Kerr D, Pollard CM, et al. Weight bias among health care professionals: a systematic review and meta-analysis. Obesity (Silver Spring). 2021;29(11):1802–1812.
   PubMed Web of Science ®Google Scholar
• Amy NK, Aalborg A, Lyons P, et al. Barriers to routine gynecological cancer screening for White and African-American obese women. Int J Obes (Lond). 2006;30(1):147–155.
   PubMed Web of Science ®Google Scholar
• Gudzune KA, Bleich SN, Richards TM, et al. Doctor shopping by overweight and obese patients is associated with increased healthcare utilization. Obesity (Silver Spring). 2013;21(7):1328–1334.
   PubMed Web of Science ®Google Scholar
• Puhl R, Suh Y. Health consequences of weight stigma: implications for obesity prevention and treatment. Curr Obes Rep. 2015;4(2):182–190.
   PubMed Web of Science ®Google Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
   PubMed Web of Science ®Google Scholar
• Tylka TL, Annunziato RA, Burgard D, et al. The weight-inclusive versus weight-normative approach to health: evaluating the evidence for prioritizing well-being over weight loss. J Obes. 2014;2014:983495.
   PubMedGoogle Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–S138.
   PubMed Web of Science ®Google Scholar
• Pandey A, Sonthalia S. Skin Tags. In: StatPearls. 2021 [cited 2022 Apr 25]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547724/
   Google Scholar
• Karadağ AS, You Y, Danarti R, et al. Acanthosis nigricans and the metabolic syndrome. Clin Dermatol. 2018;36(1):48–53.
   PubMed Web of Science ®Google Scholar
• Brown J, Clarke C, Johnson Stoklossa C, et al. Canadian adult obesity clinical practice guidelines: medical nutrition therapy in obesity management. 2021 [cited 2022 Oct 1]. Available from: https://obesitycanada.ca/guidelines/nutrition
   Google Scholar
• Ludwig DS, Aronne LJ, Astrup A, et al. The carbohydrate-insulin model: a physiological perspective on the obesity pandemic. Am J Clin Nutr. 2021;114(6):1873–1885.
   PubMed Web of Science ®Google Scholar
• Vallis TM, Macklin D, Russell-Mayhew S. Canadian adult obesity clinical practice guidelines: effective psychological and behavioural interventions in obesity management. 2020 [cited 2022 Oct 1]. Available from: https://obesitycanada.ca/guidelines/behavioural
   Google Scholar
• Nardocci M, Polsky JY, Moubarac JC. Consumption of ultra-processed foods is associated with obesity, diabetes and hypertension in Canadian adults. Can J Public Health. 2021;112(3):421–429.
   PubMed Web of Science ®Google Scholar
• Lustig RH. Ultraprocessed food: addictive, toxic, and ready for regulation. Nutrients. 2020;12(11):3401.
   PubMed Web of Science ®Google Scholar
• Hall KD, Ayuketah A, Brychta R, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30(1):67–77.e3.
   PubMed Web of Science ®Google Scholar
• Srour B, Fezeu LK, Kesse-Guyot E, et al. Ultra-processed food intake and risk of cardiovascular disease: prospective cohort study (NutriNet-Santé). BMJ. 2019;365:11451.
   Google Scholar
• Rico-Campà A, Martínez-González MA, Alvarez-Alvarez I, et al. Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study. BMJ. 2019;365:11949.
   Google Scholar
• LeFevre ML. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services task force recommendation statement. Ann Intern Med. 2014;161(8):587–593.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Wegovy® – Prescribing Information. 2021 [cited 2022 Jun 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215256s003lbl.pdf
   Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
   PubMed Web of Science ®Google Scholar
• Eli Lilly. Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. 2022 [cited 2022 Oct 26]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-fast-track-designation-tirzepatide
   Google Scholar
• US Food and Drug Administration. Xenical® - Prescribing Information 2017 [cited 2022 Nov 25]. Available from: https://www.xenical.com/pdf/PI_Xenical-brand_FINAL.PDF
   Google Scholar
• US Food and Drug Administration. Qsymia® – Prescribing Information. 2020 [cited 2022 Jun 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022580s019lbl.pdf
   Google Scholar
• US Food and Drug Administration. Contrave® – Prescribing Information. 2020 [cited 2022 Jun 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf
   Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
   PubMed Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86.
   PubMed Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Naltrexone extended-release plus bupropion extended-release for treatment of obesity. JAMA. 2015;313(12):1213–1214.
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434.
   PubMed Web of Science ®Google Scholar
• Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. JAMA. 2021;326(2):129–130.
   PubMed Web of Science ®Google Scholar
• Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Ozempic® – Prescribing Information. 2022 [cited 2022 Apr 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf
   Google Scholar
• Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–69.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Saxenda® – Prescribing Information. 2020 [cited 2022 Feb 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206321s012s013s014lbl.pdf
   Google Scholar
• ClinicalTrials.gov. A research study on how well semaglutide works in adolescents with overweight or obesity. 2022 [cited 2022 Oct 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT04102189
   Google Scholar
• Warren M, Chaykin L, Trachtenbarg D, et al. Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials. Diabetes Obes Metab. 2018;20(9):2291–2297.
   PubMed Web of Science ®Google Scholar
• Best D, Avenell A, Bhattacharya S. How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence. Hum Reprod Update. 2017;23(6):681–705.
   PubMed Web of Science ®Google Scholar
• Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–19.
   PubMed Web of Science ®Google Scholar
• Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202–210.
   PubMedGoogle Scholar
• Fitch A, Ingersoll AB. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers. Postgrad Med. 2021;133(3):310–319.
   PubMed Web of Science ®Google Scholar
• Patel D, Smith A. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. Expert Rev Clin Pharmacol. 2021;14(10):1193–1204.
   PubMed Web of Science ®Google Scholar
• Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–1061.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362.
   PubMed Web of Science ®Google Scholar
• Garvey TW, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
   PubMed Web of Science ®Google Scholar